Physician profile
Bachar Kurdi
NPI 1750483327
$2,524.35
in general payments reported to CMS, 2019-2025
14 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $275 · 2021: $385 · 2022: $444 · 2023: $280 · 2024: $363 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $607.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $564.52 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.00 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $250.05 | 2019-2022 | |
| Amgen INC. | $168.17 | 2019-2025 | Tepezza |
| Astrazeneca Pharmaceuticals Lp | $111.73 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $78.68 | 2019-2020 | |
| Abbvie INC. | $57.71 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $50.04 | 2021 | |
| Merck Sharp & Dohme LLC | $35.16 | 2019 | |
| Abbott Laboratories | $31.57 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $24.12 | 2024 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $22.87 | 2024 | |
| Ibsa Pharma INC. | $18.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bachar Kurdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.